OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr John on the Antitumor Effects of Sulindac in an Obesity-Driven Model of Endometrial Cancer

April 12th 2023

Catherine John, MD, discusses the antitumor effects of sulindac on the prevention and treatment of obesity-driven models of endometrial cancer.

Dr Rini on Retreatment With Immunotherapy Following Progression in RCC

April 11th 2023

Brian I. Rini, MD, FASCO, discusses the investigation of immunotherapy following disease progression on previous immunotherapy in patients with relapsed/refractory renal cell carcinoma.

Dr Brunner on the Heterogeneity of Relapsed Multiple Myeloma

April 11th 2023

Matthew Brunner, MD, discusses the heterogeneity of relapsed multiple myeloma and the various symptoms that patients could experience.

Dr O’Shaughnessy on Real-World Data for Tucatinib-Based Therapy in HER2+ Breast Cancer

April 11th 2023

Joyce A. O’Shaughnessy, MD, discusses real-world data for the use of the phase 2 HER2CLIMB trial regimen of tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer.

Dr Brunner on the Role of the Dermatologist in BPDCN Diagnosis and Treatment

April 11th 2023

Patrick M. Brunner, MD, discusses how collaboration between dermatologists and oncologists is critical for both accurate diagnosis and the selection of effective treatment approaches for patients with blastic plasmacytoid dendritic cell neoplasm.

Dr Brastianos Breaks Down the Basics of Meningiomas

April 11th 2023

Priscilla K. Brastianos, MD, explains the differences between low-grade meningiomas and aggressive high-grade tumors.

Dr Braun on Frontline Nivolumab Monotherapy Followed by Salvage Nivolumab/Ipilimumab in RCC

April 10th 2023

David A. Braun, MD, PhD, discusses the rationale for evaluating frontline nivolumab and salvage nivolumab plus ipilimumab in patients with advanced renal cell carcinoma in the phase 2 HCRN GU16-260 trial.

Dr Taylor on the Integration of Tagraxofusp Into the Frontline Treatment Armamentarium for BPDCN

April 10th 2023

Justin W. Taylor, MD, discusses the evolution of frontline treatment options for patients with blastic plasmacytoid dendritic cell neoplasm, including the integration of tagraxofusp-erzs into the treatment armamentarium in this disease space.

Dr Sidana on CAR T-cell Therapy in Patients With R/R Myeloma and Renal Impairment

April 10th 2023

Surbhi Sidana, MD, discusses the unmet needs for patients with relapsed/refractory multiple myeloma who could be candidates for CAR T-cell therapy but have impaired renal function, and how clinical trials for these therapies have excluded this subset of patients.

Dr Fenton on Findings from the DESTINY-Breast02 Trial in HER2+ Breast Cancer

April 10th 2023

Mary Anne Fenton, MD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.

Dr Franke on Treatment Options for NSCLC Expressing Uncommon EGFR Mutations

April 10th 2023

Aaron J. Franke, MD, MS, discusses treatment options for patients with uncommon EGFR mutations in non–small cell lung cancer.

Dr Foote on the Use of Tucatinib Plus Trastuzumab in HER2-Amplified mCRC

April 10th 2023

Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.

Dr Fenton on Trastuzumab Deruxtecan Vs Trastuzumab Emtansine in HER2+ Breast Cancer

April 7th 2023

Mary Anne Fenton, MD, discusses findings from the phase 3 DESTINY-Breast03 trial in patients with metastatic, HER2-positive breast cancer.

Dr Deol on CAR T-cell Therapy in Multiple Myeloma

April 7th 2023

Abhinav Deol, MD, discusses the efficacy and durability of CAR T-cell therapies in patients with multiple myeloma.

Dr Zonder on the Promise of Talquetamab and Cevostamab in R/R Multiple Myeloma

April 7th 2023

Jeffery Zonder, MD, discusses the derived benefit that has been derived from talquetamab and cevostamab in patients with relapsed/refractory multiple myeloma.

Dr Ryan on the Evolution of the Treatment Landscape in RCC

April 7th 2023

Christopher W. Ryan, MD, professor of medicine School of Medicine at the Oregon Health & Science University, discusses the evolution of therapeutic treatment approaches across the management treatment landscape of renal cell carcinoma.

Dr Epstein-Peterson on the Use of CAR T-Cell Therapy in MCL

April 7th 2023

Zachary Epstein-Peterson, MD, discusses the use of CAR T-cell therapy in mantle cell lymphoma and highlights questions that remain to be answered within the treatment landscape.

Dr Goldberg on Potential Strategies to Overcome Osimertinib Resistance in EGFR+ NSCLC

April 7th 2023

Sarah Goldberg, MD, MPH, discusses potential strategies to overcome osimertinib resistance in EGFR-positive metastatic non–small cell lung cancer.

Dr Sikov on the Use of CDK4/6 Inhibitors in the First-line Treatment of ER+/HER2- Breast Cancer

April 7th 2023

William M. Sikov, MD, discusses the negative outcome seen with palbociclib in the phase 3 PALOMA-2 trial, and compares this to data on other CDK4/6 inhibitors in the first-line treatment of estrogen receptor–positive, HER2-negative breast cancers.

Dr Jain on the Use of Haploidentical Donors in Myelofibrosis

April 6th 2023

Tania Jain, MBBS, discusses the use of haploidentical donors in myelofibrosis.